Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Prospective, Randomized, Double-blinded, Placebo-controlled, 4-Parallel Arm, Multi-center, Phase 2 Trial to Evaluate Efficacy and Safety of Orally Administered PLH-2301 in Elderly Patients With Sarcopenia
Authors not listed
Pluto Inc. · 2026
Abstract
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia.
Eligible subjects aged 65 years and older will be randomized to receive placebo or one of three dose levels of PLH-2301 once daily for 12 weeks.
The primary objective is to assess the effect of PLH-2301 on physical function compared with placebo.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Anonymous. (2026). A Prospective, Randomized, Double-blinded, Placebo-controlled, 4-Parallel Arm, Multi-center, Phase 2 Trial to Evaluate Efficacy and Safety of Orally Administered PLH-2301 in Elderly Patients With Sarcopenia. <em>Pluto Inc.</em>. https://clinicaltrials.gov/study/NCT07390552
Vancouver
Anonymous. A Prospective, Randomized, Double-blinded, Placebo-controlled, 4-Parallel Arm, Multi-center, Phase 2 Trial to Evaluate Efficacy and Safety of Orally Administered PLH-2301 in Elderly Patients With Sarcopenia. Pluto Inc.. 2026.
BibTeX
@misc{anon2026AProsp,
title = {A Prospective, Randomized, Double-blinded, Placebo-controlled, 4-Parallel Arm, Multi-center, Phase 2 Trial to Evaluate Efficacy and Safety of Orally Administered PLH-2301 in Elderly Patients With Sarcopenia},
author = {Anonymous},
journal = {Pluto Inc.},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
ENCell 2027
Open access · US-GOV
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia
Jiangsu Province Centers for Disease Control and Prevention 2021
Open access · US-GOV
A Single-center, Randomized, Double Blinded, Placebo Controlled, Phase 2 Clinical Trial of Recombinant COVID-19 Vaccine (CHO Cells), in the Subjects From Healthy Aged 18 Years and Above
Aventi Biotechnology Inc. 2022
Open access · US-GOV
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of AVTR101 in Sarcopenia Patients
Epirium Bio Inc. 2027
Open access · US-GOV
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MF-300 in Subjects With Age-related Sarcopenia
Chinese Academy of Medical Sciences 2021
Open access · US-GOV
A Randomized, Double-Blinded, Placebo Controlled Phase III Clinical Trial of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in Adults Aged 18 Years and Above
Amazentis SA 2018
Open access · US-GOV